Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

GeneDx Holdings (WGS) Operating Expenses: 2019-2024

Historic Operating Expenses for GeneDx Holdings (WGS) over the last 6 years, with Dec 2024 value amounting to $146.8 million.

  • GeneDx Holdings' Operating Expenses rose 66.57% to $64.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $187.8 million, marking a year-over-year increase of 25.70%. This contributed to the annual value of $146.8 million for FY2024, which is 23.53% down from last year.
  • As of FY2024, GeneDx Holdings' Operating Expenses stood at $146.8 million, which was down 23.53% from $192.0 million recorded in FY2023.
  • Over the past 5 years, GeneDx Holdings' Operating Expenses peaked at $311.1 million during FY2021, and registered a low of $146.8 million during FY2024.
  • In the last 3 years, GeneDx Holdings' Operating Expenses had a median value of $192.0 million in 2023 and averaged $213.7 million.
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 169.34% in 2020, then slumped by 36.49% in 2023.
  • Yearly analysis of 5 years shows GeneDx Holdings' Operating Expenses stood at $173.4 million in 2020, then soared by 79.40% to $311.1 million in 2021, then dropped by 2.82% to $302.4 million in 2022, then tumbled by 36.49% to $192.0 million in 2023, then fell by 23.53% to $146.8 million in 2024.